Monte Rosa Therapeutics announced its Q1 2026 financial results and business updates, highlighting positive interim clinical data for its MRT-8102 drug reducing inflammation in cardiovascular risk patients. The company plans to initiate several Phase 2 trials for MRT-8102 in various inflammatory conditions starting in H2 2026, alongside advancing other drug candidates like MRT-2359 for prostate cancer and MRT-6160 for immune diseases. Monte Rosa holds $671 million in cash and securities, supporting operations through 2029. Key upcoming milestones include clinical readouts and new trial starts across its pipeline, reflecting strong progress in developing novel molecular glue degrader therapies.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
Wendy's is running a $1 promotion on small Classic Chocolate or Vanilla Frosty from July 20 to August 23, with early access for Wendy's Rewards members on July 19 in celebration of National Ice Cream Day. The offer is redeemable via the Wendy's app a...
Inseego Corp. will release its financial results for the second quarter of 2026 on August 5, after market close. The company will hold a conference call the same day to discuss the results and business outlook. Investors can access the earnings repor...
Dyadic International has expanded its bio-industrial pipeline with a new proprietary enzyme program focused on advanced cellulose processing, building on the success of its EN3ZYME™ product. This initiative leverages Dyadic's Dapibus™ platform to str...
